2015 – Ignyta puts entrectinib on the map at ASCO and launches STARTRK-2
At ASCO 2015, Ignyta presented Phase I clinical trial data for entrectinib, demonstrating that the drug candidate was well tolerated with no drug-related serious adverse events. A recommended Phase 2 dose was determined, and a 91% response rate in patients’ meeting expected Phase 2 eligibility criteria was observed. Ignyta initiated the STARTRK-2 pivotal Phase 2 clinical trial of entrectinib in September 2015.
Pictured here are the CT scans of a 46-year-old male patient (“Mr. Z”) with NTRK1 fusion non-small cell lung cancer (NSCLC) metastatic to the brain that was refractory to carboplatin/pemetrexed, pembrolizumab, docetaxel, and vinorelbine. Mr. Z’s health rapidly deteriorated, and he was admitted to hospice care.
Mr. Z was subsequently enrolled in Ignyta’s STARTRK clinical trial of entrectinib, and the results were dramatic. Visit the Ignyta Patient Stories page to read Mr. Z’s amazing story, and the stories of other patients Ignyta has had the honor to treat in our clinical trials.